RESUMEN
Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.
Asunto(s)
Inhibidores de la Angiogénesis/efectos adversos , Anticuerpos Monoclonales Humanizados/efectos adversos , Inyecciones Intravítreas/efectos adversos , Enfermedades de la Retina/tratamiento farmacológico , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Inhibidores de la Angiogénesis/administración & dosificación , Enfermedades Cardiovasculares/inducido químicamente , Oftalmopatías/inducido químicamente , Enfermedades Gastrointestinales/inducido químicamente , Hemorragia/inducido químicamente , Humanos , Enfermedades Renales/inducido químicamenteAsunto(s)
Disco Óptico/anomalías , Fondo de Ojo , Humanos , Lactante , Imagen por Resonancia Magnética , MasculinoRESUMEN
PURPOSE: To evaluate the effect of intra-silicone injection of bevacizumab for the treatment of neovascular glaucoma (NVG) after vitrectomy for advanced proliferative diabetic retinopathy. METHODS: Bevacizumab was injected into the silicone oil in five pseudophakic eyes of five patients with NVG. The iris neovascularization (INV) and NVG had developed 1.5-4 months after vitrectomy and silicone oil tamponade. The main outcome measures were regression of INV, intraocular pressure and visual acuity. RESULTS: In all eyes, INV regressed and intraocular pressure was controlled within 7 days. Visual acuity improved in all eyes. In one patient, INV and NVG recurred 10 weeks after the injection and was successfully treated with a repeat intra-silicone bevacizumab injection. CONCLUSION: Intra-silicone injection of bevacizumab is effective in the treatment of patients with INV and NVG after vitrectomy for advanced proliferative diabetic retinopathy.
Asunto(s)
Inhibidores de la Angiogénesis/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Retinopatía Diabética/complicaciones , Glaucoma Neovascular/tratamiento farmacológico , Aceites de Silicona/administración & dosificación , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Anciano , Inhibidores de la Angiogénesis/administración & dosificación , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales Humanizados , Bevacizumab , Retinopatía Diabética/cirugía , Femenino , Glaucoma Neovascular/etiología , Glaucoma Neovascular/fisiopatología , Humanos , Inyecciones Intraoculares/métodos , Presión Intraocular , Masculino , Persona de Mediana Edad , Proyectos Piloto , Agudeza Visual , VitrectomíaRESUMEN
AIM: To compare retrobulbar haemodynamics and ipsilateral carotid wall thickness of patients with unilateral non-arteritic anterior ischaemic optic neuropathy (NAION) with their contralateral side. METHODS: Seventeen patients with unilateral NAION participated in this study. By means of Colour Doppler imaging, the blood-flow velocities of the ophthalmic artery were measured. Intima-media thickness (IMT) of common carotid and internal carotid arteries were measured using B-mode ultrasonography. Measurements of the affected side were compared with the non-involved side. RESULTS: Flow velocities in the ophthalmic arteries on the side of the eyes with NAION were significantly decreased compared with those on the side of the unaffected eyes (p<0.001). In addition, in all patients, both common and internal carotid artery IMT were significantly greater on the side of the NAION compared with the contralateral side (p<0.001). CONCLUSION: NAION may be associated with decreased retrobulbar flow velocities and increased carotid wall thickness.